An Open-label, Randomised, Parallel-group, Multicentre, Observational Trial to Evaluate Safety and Efficacy of Edoxaban Tosylate in Children From 38 Weeks Gestational Age to Less Than 18 Years of Age With Cardiac Diseases at Risk of Thromboembolic Events
Phase of Trial: Phase III
Latest Information Update: 08 Jan 2020
Price : $35 *
At a glance
- Drugs Edoxaban (Primary) ; Enoxaparin sodium; Heparin; Warfarin
- Indications Thromboembolism
- Focus Adverse reactions
- Sponsors Daiichi Sankyo Company; Daiichi Sankyo Inc
- 03 Apr 2019 Planned End Date changed from 1 Mar 2021 to 31 Dec 2020.
- 03 Apr 2019 Planned primary completion date changed from 1 Mar 2021 to 31 Dec 2020.
- 26 Mar 2018 Status changed from not yet recruiting to recruiting.